Investor Presentaiton
VGX-3100 Phase 2 Studies in HPV-Associated Vulvar and
Anal HSIL/Precancerous Dysplasias
•
Target HPV 16/18 subtypes; E6/E7 oncogenes
TRIALS: VGX-3100
•
Treat high-grade squamous intraepithelial lesions (HSIL)
Precancerous
Vulvar Dysplasia:
Interim findings
(6 months after start
of treatment)
22
Phase 2
open-label study
x33
33 women enrolled
Interim data reported for 10
Decrease in lesion
area: 80% of patients
Resolution of vulvar
dysplasia: 20% of patients
Non-detectability of HPV
16/18: 20% of patients
Phase 2
open-label study
x23
23 patients enrolled
Precancerous
Anal Dysplasia:
Interim findings
(6 months after start
of treatment)
Clearance of lesions:
50% of patients
Interim data reported for 20
Decrease in number of lesions:
75% of patients
INOVIO
POWERING DNA MEDICINESView entire presentation